M. Crump

Long‐term outcome in localized extranodal mucosa‐associated lymphoid tissue lymphomas treated with radiotherapy

R. Tsang, A. Sun, M. Pintilie, 2010, Cancer.

Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study.

A. Prica, V. Kukreti, J. Kuruvilla, 2022, Clinical lymphoma, myeloma & leukemia.

Relapse timing is associated with distinct evolutionary dynamics in DLBCL

Ryan D. Morin, R. Kridel, M. Boyle, 2023, medRxiv.

Evolution of treatment for Hodgkin's disease: a population-based study of radiation therapy use and outcome.

W. Mackillop, R. Tsang, L. Paszat, 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE‐AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR‐DLBCL) ‐ OUTCOME OF IBRUTINIB + R‐GDP

A. Prica, J. Kuruvilla, L. Shepherd, 2017 .

711 Localized mucosa-associated lymphoid tissue (MALT) lymphoma treated with radiation therapy has excellent clinical outcome

R. Tsang, A. Sun, D. Hodgson, 2003 .

NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

J. Friedberg, J. Leonard, M. Shipp, 2023, Hematological Oncology.

Long-term outcome in stage I and II follicular lymphoma following treatment with involved field radiation therapy alone

R. Tsang, A. Sun, M. Pintilie, 2004 .

CD20‐TCB (RG6026), A NOVEL “2:1” FORMAT T‐CELL‐ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN'S LYMPHOMA

G. Salles, M. Bacac, C. Carlo-Stella, 2019, Hematological Oncology.